Remibrutinib (LOU064) is a potent and highly selective covalent Inhibitor of Bruton's Tyrosine Kinase (BTK) with IC50 value of 1 nM. LOU064 (Remibrutinib) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. LOU064 (Remibrutinib) demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis.
Cell Experiment | |
---|---|
Cell lines | human monocytic cell line THP1, Human Blood B cell and Basophil |
Preparation method | The effects of LOU064 on signaling from the activating FcγR are assessed in the human monocytic cell line THP1 (ATCC, TIB-202). The THP1 cell line expresses the two activating FcγRs CD32a (FcγRII2) and CD64 (FcγRI) that signal through BTK. Briefly, 384 well culture plates are coated with pooled non-specific human IgG fraction. Serial compound dilutions are dispensed into the IgG-coated plates containing a small volume of tissue culture medium. Then THP1 cells that are pre-differentiated by vitamin D3 treatment for 5 days are added to each well. Twenty-four hours later the secretion of IL-8 in the supernatant of these culture wells is assessed by a homogenous immunoassay. |
Concentrations | 3 nM, 10 nM, 30 nM, 100 nM, 300 nM |
Incubation time | 25 min, 50 min, 75 min, 100 min |
Animal Experiment | |
---|---|
Animal models | Female Lewis rats, female C57BL/6 mice, male beagle dog |
Formulation | - |
Dosages | 1 mg/kg, 3 mg/kg |
Administration | i.v. or p.o. administration |
Molecular Weight | 507.53 |
Formula | C27H27F2N5O3 |
CAS Number | 1787294-07-8 |
Solubility (25°C) | DMSO 100 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related BTK Products |
---|
TL-925
TL-925 is a potentially first-in-class Bruton's tyrosine kinase (BTK) inhibitor that targets mast cell-mediated ocular inflammation and hypersensitivity and can be used in studies related to dry eye. |
JAK3/BTK-IN-6
JAK3/BTK-IN-6 is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively. |
NX-2127
NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells. |
DBt-10
DBt-10 is a potent BTK degrader. |
BTK-IN-27
BTK-IN-27 is a BTK inhibitor (IC50: 0.2 nM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.